Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
A study to evaluate the safety and pharmacokinetics profile of different doses of AB103
administered to patients diagnosed with Necrotizing Soft Tissue Infections that are scheduled
for an urgent surgical intervention as part of their standard of care.